The US Food and Drug Administration is currently working to pull its approval for an experimental medication intended to treat a rare autoimmune form of vasculitis that frequently damages the lungs and kidneys. The high-stakes withdrawal process follows the discovery of what the agency believes is evidence of clinical trial data manipulation.
The Road to Approval and Commercial Success
In May 2021, the agency published a comprehensive briefing document regarding the treatment developed by California-based biotechnology firm ChemoCentryx. Undecided on whether to grant approval, the agency sought advice from an independent advisory committee to determine if the medication offered meaningful improvements over existing therapies.
Trial participants demonstrated slightly higher symptom remission rates after one year. However, the FDA noted that interpreting the data proved challenging due to a suboptimal study design, with an advisory committee member stating that the treatment’s effect was not well verified.
Conversely, numerous patients and physicians viewed the data as a sign of a beneficial alternative that could reduce heavy reliance on steroids, which carry severe side effects despite high efficacy. The advisory committee ultimately voted by a narrow margin to recommend the treatment, prompting the FDA to grant official approval on October 7, 2021.
Marketed as Tavneos, the medication subsequently entered clinical use, and pharmaceutical giant Amgen acquired ChemoCentryx one year later. The treatment carries an annual cost of $220,000, and sales approached nearly half a billion dollars during the 2025 fiscal year.
Data Manipulation Allegations and Withdrawal Efforts
The commercial success continued despite a persistent investor lawsuit that inadvertently exposed what the FDA now regards as proof that ChemoCentryx staff altered data in the key clinical trial submitted for regulatory review.
As a result, the FDA issued a formal letter in April proposing the removal of Tavneos from the United States market. The agency highlighted reports of severe and occasionally fatal liver injuries while asserting that the medication currently lacks substantial evidence proving its effectiveness.
